Towards patient personalization of an Acute Lymphoblastic Leukemia Model during the oral administration of prednisone in children: Initiating the ALL Oncosimulator

In the present study, methods aiming at supporting the personalization of an Acute Lymphoblastic Leukemia (ALL) Model (ALL Oncosimulator), already in development by the In Silico Oncology Group, National Technical University of Athens, are provided. Specifically, a population pharmacokinetic model for orally administered prednisone in children with ALL is developed, and the ability of classification algorithms to predict the prednisone response using gene expression data is studied.

[1]  M. Schrappe,et al.  Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia , 2008, Annals of Hematology.

[2]  L. Notarangelo,et al.  Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. , 1984, British journal of clinical pharmacology.

[3]  Georgios Stamatakos,et al.  In Silico Oncology Part I: Clinically Oriented Cancer Multilevel Modeling Based on Discrete Event Simulation , 2010 .

[4]  H. Derendorf,et al.  A Pharmacokinetic/Pharmacodynamic Approach to Predict Total Prednisolone Concentrations in Human Plasma , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[5]  S. Armstrong,et al.  Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. , 2005, Blood.

[6]  W. Jusko,et al.  Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia , 2003, Cancer Chemotherapy and Pharmacology.

[7]  M. Relling,et al.  Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Pui,et al.  Glucocorticoid use in acute lymphoblastic leukaemia. , 2010, The Lancet. Oncology.

[9]  W. Jusko,et al.  Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. , 2002, British journal of clinical pharmacology.

[10]  Thomas Flohr,et al.  Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. , 2005, Blood.

[11]  Maria Grazia Valsecchi,et al.  Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Abbruzzese,et al.  Glucocordicoids induce G1 Arrest of Lymphoblastic Cells through Retinoblastoma Protein Rb1 Dephosphorylation in Childhood Acute Lymphoblastic Leukemia In Vivo , 2004, Cancer biology & therapy.

[13]  V. Poggi,et al.  Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia. , 2003, International journal of oncology.

[14]  R. Spang,et al.  Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia , 2007, Leukemia.